Cyclo Therapeutics, Inc. (CYTH) Research

Cyclo Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise focused on developing treatments derived from cyclodextrins for various health conditions. Its flagship therapeutic candidate, Trappsol Cyclo, holds orphan drug status and is presently in Phase III clinical trials targeting Niemann-Pick Type C disease. The company is also investigating Trappsol Cyclo's efficacy in addressing Alzheimer's disease. Beyond its drug development pipeline, the firm engages in the sale of cyclodextrins and related commodities to sectors such as pharmaceuticals and nutrition, primarily for their application in diagnostics and specialized drug formulations. Originally established in 1990 as CTD Holdings, Inc., the company adopted its current name, Cyclo Therapeutics, Inc., in September 2019 and maintains its headquarters in Gainesville, Florida.

Market snapshot

Symbol
CYTH
Price
$0.72
Day change
0.00%
Market cap
$23.6M
P/E ratio
-0.59x
52-week range
0.55-1.6199
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Analyst price target
$0.95

Peer companies

  • Elevation Oncology, Inc. (ELEV)
  • Elutia Inc. (ELUT)
  • HEXO Corp. (HEXO)
  • Invacare Corporation (IVC)
  • LakeShore Biopharma Co., Ltd (LSB)
  • MEI Pharma, Inc. (MEIP)
  • MSP Recovery, Inc. (MSPR)
  • Renalytix Plc (RNLX)

Recent insider activity

  • CONKLING WILLIAM — A-Award (27654 shares) on 2025-02-27
  • Wong Vivien — A-Award (25140 shares) on 2025-02-27
  • Cross Shawn — A-Award (28597 shares) on 2025-02-27
  • Toig Randall M. — A-Award (33311 shares) on 2025-02-27
  • STRATTAN CE RICK — A-Award (30169 shares) on 2025-02-27

Open Cyclo Therapeutics, Inc. (CYTH) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.